Literature DB >> 31732297

Gene Therapy of Critical Limb Ischemia Enters Clinical Use.

Seppo Ylä-Herttuala1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31732297      PMCID： PMC6904627          DOI： 10.1016/j.ymthe.2019.11.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  6 in total

1.  A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.

Authors:  Yongquan Gu; Shijun Cui; Qi Wang; Changjian Liu; Bi Jin; Wei Guo; Changwei Liu; Tongbin Chu; Chang Shu; Fuxian Zhang; Chengquan Han; Yue Liu
Journal:  Mol Ther       Date:  2019-10-31       Impact factor: 11.454

2.  Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.

Authors:  Sigrid Nikol; Iris Baumgartner; Eric Van Belle; Curt Diehm; Adriana Visoná; Maurizio C Capogrossi; Nicole Ferreira-Maldent; Augusto Gallino; Michael Graham Wyatt; Lasantha Dinesh Wijesinghe; Melissa Fusari; Dominique Stephan; Joseph Emmerich; Giulio Pompilio; Frank Vermassen; Emmanuel Pham; Vincent Grek; Michael Coleman; François Meyer
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

3.  Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.

Authors:  Kimmo Mäkinen; Hannu Manninen; Marja Hedman; Pekka Matsi; Hanna Mussalo; Esko Alhava; Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2002-07       Impact factor: 11.454

4.  Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.

Authors:  Ryuichi Morishita; Motokuni Aoki; Naotaka Hashiya; Hirofumi Makino; Keita Yamasaki; Junya Azuma; Yoshiki Sawa; Hikaru Matsuda; Yasufumi Kaneda; Toshio Ogihara
Journal:  Hypertension       Date:  2004-07-06       Impact factor: 10.190

Review 5.  Beperminogene perplasmid for the treatment of critical limb ischemia.

Authors:  Hiroyuki Suda; Akihiko Murakami; Toshihiro Kaga; Hideki Tomioka; Ryuichi Morishita
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-09-05

6.  Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

Authors:  Richard J Powell; Michael Simons; Farrel O Mendelsohn; George Daniel; Timothy D Henry; Minako Koga; Ryuichi Morishita; Brian H Annex
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690
  6 in total
  3 in total

1.  In silico performance analysis of web tools for CRISPRa sgRNA design in human genes.

Authors:  Cristian N Nuñez Pedrozo; Tomás M Peralta; Fernanda D Olea; Paola Locatelli; Alberto J Crottogini; Mariano N Belaich; Luis A Cuniberti
Journal:  Comput Struct Biotechnol J       Date:  2022-07-13       Impact factor: 6.155

2.  Two-Stage Gene Therapy (VEGF, HGF and ANG1 Plasmids) as Adjunctive Therapy in the Treatment of Critical Lower Limb Ischemia in Diabetic Foot Syndrome.

Authors:  Piotr Barć; Maciej Antkiewicz; Katarzyna Frączkowska-Sioma; Diana Kupczyńska; Paweł Lubieniecki; Wojciech Witkiewicz; Małgorzata Małodobra-Mazur; Dagmara Baczyńska; Dariusz Janczak; Jan Paweł Skóra
Journal:  Int J Environ Res Public Health       Date:  2022-10-06       Impact factor: 4.614

3.  Double VEGF/HGF Gene Therapy in Critical Limb Ischemia Complicated by Diabetes Mellitus.

Authors:  Piotr Barć; Maciej Antkiewicz; Barbara Śliwa; Katarzyna Frączkowska; Maciej Guziński; Tomasz Dawiskiba; Małgorzata Małodobra-Mazur; Wojciech Witkiewicz; Diana Kupczyńska; Bartłomiej Strzelec; Dariusz Janczak; Jan Paweł Skóra
Journal:  J Cardiovasc Transl Res       Date:  2020-09-01       Impact factor: 4.132
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.